SHORT HILLS, N.J.–(BUSINESS WIRE)–Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the second quarter and six months ended June 30, 2022. “We have made excellent progress on the strategic realignment announced in July. We … [Read more…]

Vendors selected for the report are noteworthy, visionary, and innovative in their respective fields LOS ANGELES–(BUSINESS WIRE)–Pearl, the global leader in dental AI solutions, announced today that it has been included on the 2022 list of “Hot Vendors” in Computer Visioni by Aragon Research, Inc. The firm’s report identifies vendors whose technology provides transformative capabilities … [Read more…]

BOTHELL, Wash.–(BUSINESS WIRE)–Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. (“Daiichi Sankyo”) relating to the parties’ 2008 collaboration agreement for the use of Seagen’s antibody-drug conjugate (ADC) technology. The arbitrator ruled in favor of Daiichi Sankyo, citing statute of limitations and disagreement with Seagen … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Erosive Esophagitis – Epidemiology Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering. This “Erosive Esophagitis – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Erosive Esophagitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Alopecia – Epidemiology Forecast to 2032” report has been added to ResearchAndMarkets.com’s offering. This “Alopecia – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Alopecia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Alopecia Epidemiology … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global OTC Artificial Tears Market (2022-2027) by Product, Container Type, Formulation, Application, Distribution Channel, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering. The Global OTC Artificial Tears Market is estimated to be USD 4.85 Bn in 2022 and is expected to reach USD … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Smart Insulin or Glucose Responsive Insulin Market (2022-2027) by Drug, Delivery Devices, Disease, Type, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering. The Global Smart Insulin or Glucose Responsive Insulin Market is estimated to be USD 3.12 Bn in 2022 and is … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Face Shields Market, By Product, By Application, and By Region – Size, Share, Outlook, and Opportunity Analysis, 2022 – 2028” report has been added to ResearchAndMarkets.com’s offering. A face shield is a personal protective equipment (PPE) used to protect the wearer’s face from a physical hazard, chemical splashes, energy or radiation, and biological … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Surgical Microscopes Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031” report has been added to ResearchAndMarkets.com’s offering. This report on the global surgical microscopes market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the … [Read more…]

PARIS–(BUSINESS WIRE)–Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) … [Read more…]